DDInter1431 DDInter1376
Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Perindopril {u} (Compound) resembles {v} (Compound) Trandolapril
Perindopril {u} (Compound) resembles {v} (Compound) Quinapril
Perindopril {u} (Compound) treats {v} (Disease) coronary artery disease
Perindopril {u} (Compound) binds {v} (Gene) ACE
Perindopril {u} (Compound) upregulates {v} (Gene) SATB1
Perindopril {u} (Compound) downregulates {v} (Gene) HAT1
Perindopril {u} (Compound) causes {v} (Side Effect) Muscular weakness
Perindopril {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Perindopril {u} may cause a minor interaction that can limit clinical effects when taken with {v} Erythropoietin
Perindopril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epoprostenol
Perindopril (Compound) resembles Trandolapril (Compound)
Perindopril (Compound) resembles Quinapril (Compound)
Perindopril (Compound) treats coronary artery disease (Disease)
Perindopril (Compound) binds ACE (Gene)
Perindopril (Compound) upregulates SATB1 (Gene)
Perindopril (Compound) downregulates HAT1 (Gene)
Perindopril (Compound) causes Muscular weakness (Side Effect)
Perindopril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Perindopril may cause a minor interaction that can limit clinical effects when taken with Erythropoietin
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol